Entheias is developing a patent‑protected immunology platform that enhances therapeutic vaccine efficacy for chronic hepatitis B patients who do not respond to existing vaccines. By targeting the underlying mechanism of vaccine failure, their approach aims to enable the immune activation needed for functional cure, addressing a large, unmet patient population with no direct competitors.
Funding
Funding not disclosed
Founders
Product
Problem
Therapeutic vaccines for chronic hepatitis B fail to elicit an immune response in roughly 40% of patients, leaving a sizable non‑responder segment without effective treatment options. All current vaccine candidates share the same mechanistic limitation, creating a gap in the pathway toward functional cure.
Solution
Entheias has created a patent‑protected immunology platform that specifically addresses the underlying cause of therapeutic vaccine failure in chronic HBV patients. The platform introduces a novel immune‑activating mechanism designed to work alongside emerging combination‑therapy regimens, thereby expanding the proportion of patients who can achieve functional cure. By targeting this mechanistic gap, Entheias offers a differentiated approach with no direct competitors in the global pipeline, aiming to serve a large, unmet patient population.
Target Audience
Primary customers are biopharmaceutical companies developing combination therapies for chronic hepatitis B that require an effective therapeutic vaccine component.
Features
- Patent‑protected platform that modulates immune pathways distinct from existing therapeutic vaccines
- Novel immunological mechanism engineered to overcome the root cause of vaccine non‑responsiveness
- Compatibility with a range of combination‑therapy backbones currently advancing toward HBV cure
- Designed for integration into existing clinical development programs without requiring new delivery technologies
- Focused on the 40% non‑responder cohort, representing a substantial unmet market need